NCT03126591 2024-10-23
A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Eli Lilly and Company
Phase 1 Completed
Clinical Trials
8 trialsNCT03985722 2023-03-27
OLATRASTS
Grupo Espanol de Investigacion en Sarcomas
Phase 1 Unknown
NCT02377752 2021-02-17
A Study of Olaratumab in Japanese Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03283696 2020-09-10
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Eli Lilly and Company
Phase 1 Completed
NCT02677116 2020-05-20
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02326025 2019-11-21
A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma
Eli Lilly and Company
Phase 1 Completed
NCT02783599 2019-08-12
A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma
Eli Lilly and Company
Phase 1 Completed
NCT00768391 2011-06-28
Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available
Eli Lilly and Company
Phase 1 Completed